Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

Published:2019-01 Issue: Volume:39 Page:207-214
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Karachaliou Niki,Cardona Andres Felipe,Bracht Jillian Wilhelmina Paulina,Aldeguer Erika,Drozdowskyj Ana,Fernandez-Bruno Manuel,Chaib Imane,Berenguer Jordi,Santarpia Mariacarmela,Ito Masaoki,Codony-Servat Jordi,Rosell Rafael

Funder

La Caixa Foundation

Instituto de Salud Carlos III

Marie Skłodowska-Curie Innovative Training Networks European Grant

Spanish Association Against Cancer

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference38 articles.

1. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

2. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations;Mok;J Clin Oncol,2018